U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07777211) titled 'A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer' on Aug. 17.
Brief Summary: This is a Phase I/IIa, multicenter study designed to evaluate the safety, tolerability, and efficacy of GKL-006 injection in patients with ductal adenocarcinoma of pancreas.
Study Start Date: Aug. 14, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Pancreatic Cancer
Ductal Adenocarcinoma of Pancreas
Intervention:
BIOLOGICAL: GKL-006 injection
GKL-006 injection will be administered at the protocol-defined dose every 2 weeks. Participants in Phase I will receive the assigned low or high dose, and recommended dose...